Lupin today announced the appointment of Dr Shahin Fesharaki as Global Chief Scientific Officer, a statement from the company informed.
Dr Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics and specialty products, it further said.
With nearly 30 years’ experience in drug development in leading global pharma companies, Dr Fesharaki most recently served as the Chief Scientific Officer and Global Head, R&D, Hikma Pharma. Prior to that, he held various leadership positions in Teva, Allergan/Actavis, Watson Pharma and Apotex.
Dr Fesharaki has development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.